Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.
about
The Potential Protective Effects of Polyphenols in Asbestos-Mediated Inflammation and Carcinogenesis of MesotheliumUse of Mesothelial Cells and Biological Matrices for Tissue Engineering of Simple Epithelium SurrogatesApplication of proteomics to soft tissue sarcomasMesothelioma response to carbon nanotubes is associated with an early and selective accumulation of immunosuppressive monocytic cellsMesothelioma tumor cells modulate dendritic cell lipid content, phenotype and functionA multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomasCOX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.What's the place of immunotherapy in malignant mesothelioma treatments?Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.Investigational approaches for mesothelioma.Changes in global gene expression associated with 3D structure of tumors: an ex vivo matrix-free mesothelioma spheroid modelKinetics of host cell recruitment during dissemination of diffuse malignant peritoneal mesothelioma.Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesotheliomaImmune responses and immunotherapeutic interventions in malignant pleural mesothelioma.The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markersThe Role of Regulatory T Cells in Mesothelioma.An array of possibilities in cancer research using cytokine antibody arrays.Inflammation in malignant mesothelioma - friend or foe?Expression of cancer-associated molecules in malignant mesotheliomaNew diagnostic and molecular characteristics of malignant mesothelioma.Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact.Feasibility of immunotherapy for lymphangioleiomyomatosis.Fiber types, asbestos potency, and environmental causation: a peer review of published work and legal and regulatory scientific testimony.Proteomic profiling of the tumor microenvironment: recent insights and the search for biomarkers.Novel targeted therapies and vaccination strategies for mesothelioma.Malignant pleural mesothelioma: from the bench to the bedside.Dendritic cell-based immunotherapy in mesothelioma.Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.Immunotherapy prospects in the treatment of lung cancer and mesothelioma.Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).FoxO1 regulates apoptosis induced by asbestos in the MT-2 human T-cell line.Malignant Peritoneal Mesothelioma: Characterization of the Inflammatory Response in the Tumor Microenvironment.Anti-CTLA-4 therapy for malignant mesothelioma.CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy.Decreased CXCR3 expression in CD4+ T cells exposed to asbestos or derived from asbestos-exposed patients.
P2860
Q26750451-5D598028-0CEF-4C4C-80FF-437BC15E69C5Q26782723-88B70646-A985-47B9-93EA-A725AE94126EQ28385995-153AC8FB-2E67-4F56-B5B2-D62E8DB1C8E5Q28387268-72166043-6EBA-4273-B3AB-749CB954F053Q28392070-D8DD1D0C-329F-4D57-9C9D-84BFE02D883CQ28392105-ACE5935D-5A43-4AF2-9CA9-D5F080CB7483Q33678308-0A350586-43C7-4466-83DC-0EBEBAA8EB9FQ33699231-94782600-1159-49DC-80BE-9BC98B4FA5B1Q33781142-18C2F7C7-A705-400B-BAA7-04BB6D76A02AQ33871059-B967CA62-1B11-46F5-8C63-F9D962EA3917Q34122791-85C2306B-B546-4037-B235-8C78A29742EAQ34142500-3453D87A-2B13-4A82-89FC-9406C5CFE9B1Q34293068-A953CC79-A0F7-4AA0-AA0C-2B18ED1F4F68Q34318460-BEA13D35-CBDB-4F0B-B774-B9A04D8F88E3Q34618985-A682C28E-64F6-4C3B-B6B2-81FEE93D1F4EQ34788477-2D95DB0B-6D5A-4DB9-9D87-959C5E03656BQ35176037-FD6CD308-A841-4648-B361-B84E24F82E57Q35711576-99B544B3-29FC-44BA-A852-8581C251CB36Q35799028-2258252F-F301-45D8-90FA-47A663CFDF72Q36101238-07C4995C-699A-424C-8D7F-DEB72CA2DE56Q36787259-A8BAAF79-5E69-49F4-B36E-50127BE8F2BEQ37090789-0794E19E-80F4-4ED2-8828-2F6B36437C0DQ37281015-F0DCF5A2-9D40-48CC-8396-592093D2B667Q37360580-61FBBA62-1F95-4D62-A5A0-BF8CF55EB5EFQ37457750-884BA9A2-14C5-4A4C-ADFC-6D00D756CCF4Q37462607-5EC2EF3F-F95D-4FB7-93B3-0EF93388C4C2Q37507884-5FFE2E6E-5180-44FA-99C4-9C49AECC9D60Q37689678-486D81C9-E547-4E15-8A41-1A0878883DC4Q37855667-51BDD753-7ED4-4554-B8FE-B7F64B202ECFQ38019747-2E2F75D5-EEAD-4554-95EA-BEF646914549Q38059514-49CBB56E-0FF4-4CC9-ABAB-17721FEE8B0BQ38180749-0E65FEAD-01F5-4AE1-B4F2-A4E0272FF5F4Q38390104-A5A41912-2F80-4880-977F-4496DCCD6047Q38399051-A1F0C59F-6853-449A-9E66-12F5195085F6Q38780904-C4DD180B-7FDC-4C17-BF8C-0122F0D0DD29Q38945362-2B638A77-524D-4D7C-B2F9-80BBB1FEFF4FQ39148274-418BE521-4D13-449E-8893-AA6B75ECC3C5Q39305346-30319811-B437-4EC5-883E-F64F94CD9EE2Q39393666-51EF7205-FAAC-4C1F-99DC-44CD39D9CEBEQ39584952-A9AB7C28-414B-4AC1-9709-314CECA0999F
P2860
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Mesothelioma environment compr ...... hat suppress immune responses.
@en
type
label
Mesothelioma environment compr ...... hat suppress immune responses.
@en
prefLabel
Mesothelioma environment compr ...... hat suppress immune responses.
@en
P2093
P1476
Mesothelioma environment compr ...... hat suppress immune responses.
@en
P2093
B N Lambrecht
H C Hoogsteden
J P J J Hegmans
P304
P356
10.1183/09031936.06.00135305
P577
2006-03-15T00:00:00Z